Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 7 of 7 for “"Intestinal L cells"”.
-
Identification of genipin as a potential treatment for type 2 diabetes
… insulin resistance, and the dysfunction of β-cells. While there are several therapies for T2D, there is no effective treatment that can reverse the functional decline of pancreatic β cells in T2D patients. Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by human intestinal L …
-
Investigation of the effect of acute radiation on enteroendocrine L-cell health and function
… peptide hormone in the enhancement of proper intestinal function, proliferation of intestinal tissue and inhibition of enterocyte apoptosis, is a known treatment option of malabsorption disorders of the intestines. Recent developments have demonstrated that exogenous GLP-2 treatments attenuate …
-
The protective role of hydrogen sulfide from obesity-associated metabolic stress in GLP-1 regulation
… glucagon-like peptide-1 (GLP-1) secreted from intestinal L-cells. Recently, the gasotransmitter hydrogen sulfide (H2S) has been implicated in the enhancement of GLP-1 secretion. We hypothesized that H2S can reduce the oxidative stress caused by PA and GA, and play a protective role in L-cell …
-
Short and Long Chain Free Fatty Acids Differentially Regulate Glucagon-like Peptide-1 and Peptide YY Transcript Levels in Enteroendocrine Cells (STC-1)
… hormones after chronic exposure to fatty acids. Intestinal secretin tumor cell line (STC-1 cells) was used as a representative for intestinal L-cells. Quantitative real-time PCR analysis was used to determine the changes in RNA transcripts. Overall, there was a decrease in the 3-hour timeline, …
-
Secretagogin is Essential for Circadian GLP-1 Secretion and is Altered in a Model of Type 2 Diabetes
Glucagon-like Peptide-1 (GLP-1) is secreted from intestinal L-cells in response to food intake to upregulate glucose-dependent insulin secretion. GLP-1 based therapies are therefore employed in the treatment of type 2 diabetes (T2D) through the use of receptor agonists or degradation inhibitors, …
-
Development of a pancreatic substitute based on genetically engineered intestinal endocrine cells
… work is to engineer autologous insulin-secreting intestinal endocrine cells as a non-beta cell approach to alleviate donor cell shortage and immune rejection issues associated with islet transplantation. These cells have been chosen for their endogenous similarity to beta cells, but generating …
-
Gastric and small intestinal motor function in health and disease - implications for glucose absorption, incretin hormone release, and postprandial blood glucose regulation.
… polypeptide (GIP), are secreted by the L and K cells in the intestines respectively, in response to nutrient-gut interactions. Their main function is the augmentation of glucose-induced insulin release from the pancreas, the so called “incretin effect”. GLP-1 also possesses a potent inhibitory …